Standard BioTools Inc. Increase Decrease In Operating Lease Liability
Standard BioTools Inc. (LAB) reported Increase Decrease In Operating Lease Liability of -$2.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-05
- Standard BioTools Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$1.34M.
- Standard BioTools Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$1.49M.
- Standard BioTools Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$1.68M.
- Standard BioTools Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$1.67M.
- Standard BioTools Inc. increase decrease in operating lease liability for fiscal 2025 was -$6.42M.
- Standard BioTools Inc. increase decrease in operating lease liability for fiscal 2024 was -$5.86M.
- Standard BioTools Inc. increase decrease in operating lease liability for fiscal 2023 was -$3.76M.
- Standard BioTools Inc. increase decrease in operating lease liability for fiscal 2022 was -$3.11M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$2.83M 10-Q · filed 2026-08-05 | -$4.51M derived: sum of 3 quarters · filed 2026-08-05 | -$6.18M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$1.49M 10-Q · filed 2026-05-06 | -$3.17M derived: sum of 2 quarters · filed 2026-05-06 | -$4.84M derived: sum of 3 quarters · filed 2026-05-06 | -$6.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$3.35M derived: sum of 2 quarters · filed 2026-03-16 | -$4.91M derived: sum of 3 quarters · filed 2026-08-05 | -$6.42M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$1.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$3.23M derived: sum of 2 quarters · filed 2026-08-05 | -$4.74M 10-Q · filed 2025-11-04 | -$6.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$3.06M 10-Q · filed 2026-08-05 | -$4.51M derived: sum of 3 quarters · filed 2026-08-05 | -$5.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$1.50M 10-Q · filed 2026-05-06 | -$2.95M derived: sum of 2 quarters · filed 2026-05-06 | -$4.38M derived: sum of 3 quarters · filed 2026-05-06 | -$5.91M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$2.88M derived: sum of 2 quarters · filed 2026-03-16 | -$4.41M derived: sum of 3 quarters · filed 2026-03-16 | -$5.86M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$2.96M derived: sum of 2 quarters · filed 2025-11-04 | -$4.41M 10-Q · filed 2025-11-04 | -$5.37M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-06-30 | -$1.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | -$2.98M 10-Q · filed 2025-08-15 | -$3.94M derived: sum of 3 quarters · filed 2026-03-16 | -$4.91M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-03-31 | -$1.45M 10-Q · filed 2025-05-06 | -$2.41M derived: sum of 2 quarters · filed 2026-03-16 | -$3.38M derived: sum of 3 quarters · filed 2026-03-16 | -$4.31M derived: sum of 4 quarters · filed 2026-03-16 |
| 2023-12-31 | -$957.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$1.92M derived: sum of 2 quarters · filed 2026-03-16 | -$2.86M derived: sum of 3 quarters · filed 2026-03-16 | -$3.76M 10-K · filed 2026-03-16 |
| 2023-09-30 | -$966.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$1.90M derived: sum of 2 quarters · filed 2024-11-06 | -$2.80M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$935.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$1.84M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | -$901.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$3.11M 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |